For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
DelveInsight's, " Benign Prostatic Hyperplasia - Pipeline Insight, 2020," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Benign Prostatic Hyperplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
- Global coverage
Benign Prostatic Hyperplasia: Understanding
Benign prostatic hyperplasia: Overview
Benign prostatic hyperplasia (BPH) refers to the change in the size of the prostate and not the potential symptoms that it may cause, which are usually referred to as lower urinary tract symptoms (LUTS). LUTS may be primarily irritative, obstructive, or mixed. Men with BPH may be asymptomatic, respond to lifestyle changes, or require medical or surgical therapy; symptoms are more common as men age.
The symptoms of Benign prostatic hyperplasia include:
- Obstructive Symptoms - Sensation of incomplete bladder emptying, Straining to void,Urinary hesitancy, Weak urinary stream
- Irritative Symptoms - Dysuria, Nocturia, Urinary frequency, Urinary urgency
Several key diagnostic tools and investigations are used to diagnose BPH in men who present with LUTS. The first and most important tool in the assessment and diagnosis of BPH is the medical history of the patient. By taking a detailed history, one can establish potential causes and relevant comorbidities of LUTS, some of which might contribute to LUTS. A physical examination, including a digital rectal examination (DRE) and urinalysis, is the next step in diagnosis. Further investigations, such as uroflowmetry and measuring PVR volume, should help to confirm the presence of obstructive symptoms attributable to BPH.
Pharmacologic treatment- Men with moderate to severe LUTS from BPH (AUASI score of 8 or higher) or mild LUTS that are deemed bothersome by the patient may be offered pharmacologic treatment. The 2 major classes of medications for BPH are alpha-adrenergic blockers and 5-alpha reductase inhibitors. The PDE-5 inhibitor tadalafil is also approved by the Food and Drug Administration (FDA) for the treatment of BPH.
Non Pharmacologic treatment- In men with mild LUTS symptoms from BPH (usually defined as an AUASI score of 0-7), medical or surgical treatment is not required. In the Medical Therapy of Prostatic Symptoms Study,23 fewer than 5% of men with mild symptoms who did not receive treatment had a progression of their symptoms as defined by a 4-point or greater increase in their AUASI score. No cases of acute kidney injury due to obstructive uropathy occurred.
Benign prostatic hyperplasia Emerging Drugs Chapters
This segment of the Benign prostatic hyperplasia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Benign prostatic hyperplasia Emerging Drugs
- Topsalysin: Sophiris Bio
Topsalysin is a modified pore forming protein (proaerolysin) in phase III clinical trials for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. It was developed by Sophiris Bio, then licensed to Kissei for development.
- OPK88004: Eli Lilly and Company
OPK88004 is a Phase 2 drug that is a selective androgen receptor modulator. OPK-88004 has the ability to serve as an antagonist to androgen receptors in the prostate, resulting in decreased prostate specific antigen (PSA) levels, and as an agonist resulting in increased anabolic effects, such as increased lean body mass and physical function and decreased fat mass. The originator of this was Eli Lilly and now licensed by OPKO Health.
Further product details are provided in the report ..
Benign prostatic hyperplasia: Therapeutic Assessment
This segment of the report provides insights about the different Benign prostatic hyperplasia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Benign prostatic hyperplasia
There are approx. 30+ key companies which are developing the therapies for Benign prostatic hyperplasia. The companies which have their Benign prostatic hyperplasia drug candidates in the most advanced stage, i.e. phase III include, Sophiris Bio.
DelveInsight's report covers around 30+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Benign prostatic hyperplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Benign prostrate hyperplasia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Benign prostatic hyperplasia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Benign prostatic hyperplasia drugs.
- The companies and academics are working to assess challenges and seek opportunities that could influence Benign prostatic hyperplasia R&D. The therapies under development are focused on novel approaches to treat/improve Benign prostatic hyperplasia.
- In November 2020, Urovant Sciences has agreed to be fully acquired by largest investor and close partner Sumitovant BioPharma and the deal is set to be finalized in early 2021.
Benign prostatic hyperplasia Report Insights
- Benign prostatic hyperplasia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Benign prostatic hyperplasia Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Benign prostatic hyperplasia s drugs?
- How many Benign prostatic hyperplasia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Benign prostatic hyperplasia?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Benign prostatic hyperplasia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Benign prostatic hyperplasia and their status?
- What are the key designations that have been granted to the emerging drugs?
- ASKA Pharmaceutical
- Otsuka Pharmaceutical
- Eli Lilly and Company
- XuanZhu Pharma
- Aiviva BioPharma
- Veru Helathcare
- Boryung Pharmaceutical